Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,044 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.
Zhou Y, Wang B, Qu J, Yu F, Zhao Y, Li S, Zeng Y, Yang X, Chu L, Chu X, Li Y, Zou L, Guo T, Ye L, Liang F, Wang S, Liu Q, Ni J, Zhu Z. Zhou Y, et al. Among authors: yu f. Lung Cancer. 2020 Dec;150:178-185. doi: 10.1016/j.lungcan.2020.10.018. Epub 2020 Nov 5. Lung Cancer. 2020. PMID: 33186860
Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer With Brain Metastases.
Yu F, Ni J, Zeng W, Zhou Y, Guo T, Zeng Y, Zhao Y, Li S, Li Y, Yang X, Zou L, Wang S, Liu Q, Li Y, Chu L, Chu X, Ye L, Yu W, Zhu Z. Yu F, et al. Among authors: yu w. Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):804-815. doi: 10.1016/j.ijrobp.2021.05.125. Epub 2021 May 29. Int J Radiat Oncol Biol Phys. 2021. PMID: 34058255
Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
Xu D, Yu F, Guo T, Zhou Y, Zhang J, Li Y, Jiang S, Mao J, Yang X, Chu L, Chu X, Wang S, Ni J, Zhu Z. Xu D, et al. Among authors: yu f. Br J Radiol. 2022 Aug 1;95(1136):20220035. doi: 10.1259/bjr.20220035. Epub 2022 Jun 9. Br J Radiol. 2022. PMID: 35611637 Free PMC article.
Selenium: 48-year journey of global clinical trials.
Wu Y, Pei J, Xu Y, Yu F, Xu S. Wu Y, et al. Among authors: yu f. Mol Cell Biochem. 2025 Jan 4. doi: 10.1007/s11010-024-05202-x. Online ahead of print. Mol Cell Biochem. 2025. PMID: 39755855 Review.
10,044 results
You have reached the last available page of results. Please see the User Guide for more information.